A daily pill just doubled survival time for advanced pancreatic cancer
BY THE OPTIMIST DAILY EDITORIAL TEAM In a 500-patient trial at American Society of Clinical Oncology’s (ASCO) annual meeting in Chicago, a daily pill called daraxonrasib doubled average survival time in patients with advanced pancreatic cancer. Those on the drug lived for an average of 13.2 months. Those on standard chemotherapy lived for 6.6 to 6.7 months. Side effects were fewer, too. Oncologists at the conference called it a grand slam. It’s also what four decades of failing to crack one spec
The science section covers breakthroughs in medicine, physics, biology, and technology. We surface discoveries that expand what humanity can do, from new treatments reaching clinical trials to engineering feats that seemed impossible a decade ago. Every link goes to the original publisher so you can read the full study or press release yourself.
BY THE OPTIMIST DAILY EDITORIAL TEAM For decades, researchers looked for the seat of magnetoreception in all the obvious…
BY THE OPTIMIST DAILY EDITORIAL TEAM There is something disquieting about the idea that a law governing slavery could st…
Earth Observatory Science Earth Observatory Tyndall’s Trail of Bergs Earth Earth Observatory Image of the Day EO Explore…
1 min readPreparations for Next Moonwalk Simulations Underway (and Underwater) HomeCharacteristics The Flight Dynamics R…